FDA advisers vote against approval of Capricor’s DMD therapy in chaotic adcomm meeting
FDA advisers vote against approval of Capricor’s DMD therapy in chaotic adcomm meeting. Reported by BioSpace on 2026-07-29.
Capricor Therapeutics
Capricor Therapeutics (NASDAQ: CAPR) is a cell therapy company headquartered in Beverly Hills, California, USA.
Company Info
Upcoming Milestones & Key Dates
2026-08-11
Earnings
Q2 2026 earnings
2026-09-30
Regulatory
FDA AdComm for deramiocel (DMD cardiomyopathy)
2026-12-15
Regulatory
PDUFA target for deramiocel
Clinical Development Pipeline
Deramiocel (CAP-1002)
Target: Cardiosphere-derived cellsCAP-1002
Target: Cardiosphere-derived cellsStealthX
Target: Engineered exosomeRecent News
Updated: FDA adcomm votes down Capricor's DMD therapy over efficacy
Updated: FDA adcomm votes down Capricor's DMD therapy over efficacy. Reported by Endpoints News on 2026-07-29.
UPDATE: FDA disputes Capricor’s claims of Phase 3 success for DMD cell therapy
UPDATE: FDA disputes Capricor’s claims of Phase 3 success for DMD cell therapy. Reported by BioSpace on 2026-07-27.
Capricor thrown for another loop as FDA sets adcomm for DMD cardiomyopathy therapy
Capricor thrown for another loop as FDA sets adcomm for DMD cardiomyopathy therapy.
Leadership Team
Linda Marbán
CEO & Co-founder
AJ Bergmann
CFO
Karen B. Goldschmidt, MD
VP, Clinical Operations
Careers & Job Openings